Editor in Chief Dr KK Aggarwal, Padma Shri Awardee Dated:23 March,2020
Covid-19: French researcher reports successful drug trial
Amid the novel coronavirus scare around the world, a French researcher has reported successful trial of a new treatment line for Covid-19, with early tests suggesting it can stop the virus from becoming contagious in just six days. According to connexionfrance.com, Professor Didier Raoult from hospital l'Institut Hospitalo-Universitaire (IHU Mediterranee), put up a video to explain the trials held earlier this week.
PARIS: Amid the novel coronavirus scare around the world, a French researcher has reported successful trial of a new treatment line for Covid-19, with early tests suggesting it can stop the virus from becoming contagious in just six days....read more
CMAAO IMA HCFI CORONA Myth Busters 8
Coronaviruses have same weight as other viruses
COVID-19 virus is physically larger and heavier than other known respiratory viruses. COVID-19 infects hosts through mucus droplets but its infectious range is lower than other viruses as its mass affects the distance it can travel before giving in to gravity. Coronaviruses can only travel about one to two meters, less than seven feet, before falling to the ground. More infectious viruses such as measles or chickenpox, are much lighter and remain airborne on tiny dust particles. ....read more
CMAAO IMA HCFI Corona Myth Buster 9
Doubling time is same for each country
Why do we place our hands over the flame?
Flame is the “flame” of true knowledge. At the end of any aarti, we place our hands over the flame and then touch our eyes and the top of the head. It means – “May the light that illuminated the Lord light up my vision; May my vision be divine and my thoughts noble and beautiful.”
Health Sutras By Dr K K Aggarwal
Stop using single-use (or disposable) plastics.
Healthcare News Monitor
The Times of India- Rupali Mukherjee
Mumbai: Major pharma companies assured the Prime Minister on Saturday there would not be any shortage of critical medicines in the wake of Covid-19 outbreak, ever after April, with supplies of certain raw materials having resumed from China. Significantly, the industry said there were enough stocks of hydroxychloroquine, a medicine used for rheumatoid arthritis and malaria, in the country, if there was need to use it as a potential treatment for Covid-19, sources told TOI. With a global race to develop effective treatments for the dreaded virus, hydroxychloroquine has emerged reportedly as one of the frontrunners globally. PM Narendra Modi held a video conference with CEOs of top drug companies like Zydus Cadila, Dr Reddy’s, Sun Pharma and GSK, industry associations IPA, IDMA and OPPI, AiMed, bulk drug manufacturers’ and chemist associations including AIOCD, to assess supplies of key medicines and critical devices like ventilators in view of the rising number of Covid-19 cases. Earlier, the Union Cabinet approved a Rs 9,940 crore incentive package for bulk drugs and Rs 3,820 crore for medical devices. Main producers of hydroxychloroquine include Zydus, IPCA Laboratories and Cipla, while a majority of the drug is exported to US. Amidst the surge in demand, a shortage of the generic drug in US is being feared reportedly, according to American Society of Health-System Pharmacists. Regarding the stocks of medicines in India, earlier the industry had conveyed that it had an inventory for three to four months till March-April, after which it could face supply disruption. Shortages were feared mostly in key raw materials and APIs (active pharmaceutical ingredients) on which there is complete dependence on China including paracetamol, several antibiotics and vitamins, due to the lockdown in China’s Hubei’s province in the wake of Coronavirus outbreak. This had led to the government to impose export restrictions on 26-odd APIs earlier this month.
Hindustan Times- Rhythma Kaul
The government’s decision to incentivise manufacturing of active pharmaceutical ingredients (APIs) and key starting materials (KSMs) for drugs under Make in India will work well in the creation of a self-sufficient healthcare ecosystem in the country, and reduce dependence on imports, say experts in the field. “India has the capability and competence to manufacture all APIs. The announcement by the Government will help revive the API industry in the country and will help the sector regain the dominance that was lost over the years. The investment in creating bulk drug parks is an important step in the right direction for the development of the industry,” said Satish Reddy, IPA president, and chairman, Dr Reddy’s Laboratories, in a statement. India is the pharmacy of the world and contributes 20% to the global generics market. As per government estimates, every third tablet sold in the US is from India. However, the industry is dependent on China for many APIs and KSMs, which go into the manufacturing of formulations.
Coronavirus in India: 60,000 tests possible in a week; every state to get dedicated COVID-19 hospital
Business Today- Joe C Mathew
The central government has asked every state to ready at least one hospital earmarked only for treating COVID-19 cases. It has also approved three private labs for testing COVID-19 cases to ramp up the testing facilities. Addressing the daily briefing of COVID-19 preparedness of the government, Health Ministry officials said that the country has the ability to test around 60,000 cases a week, however, efforts are being made not to do indiscriminate testing. More applications from private labs are under consideration for approvals, they said. The names of the approved private laboratories were not disclosed. "We have tested 5000 samples last week. We have the capacity to do more, but we want to ramp up testing as per the requirement", Balram Bhargava, director general ICMR and Secretary Department of Health Research "Our response is graded. Depending on the number cases, the number of isolation beds and ventilators will be ramped up. We have ordered for 1,200 new ventilators. We will be ready to face any emerging situation", Lav Agarwal, joint secretary, Health Ministry said. The COVID hospital facilities will be separate, earmarked only for COVID cases in every state. In Delhi, an 800-bed section in AIIMS is being earmarked to handle COVID cases, the officials said. On the number of testing centres, the officials said that 111 government labs are equipped to handle COVID samples. "Three private labs have been approved, more labs have approached, with thousands of collection centres they have, testing can be ramped if need be", they said.
NDTV- Manish Kumar, Saurabh Gupta
Three coronavirus deaths were reported from Maharashtra's Mumbai, Bihar and Gujarat today, which takes the total number of deaths linked to COVID-19 in India to seven. In Bihar, a 38-year-old man who had recently traveled to Qatar, died of renal failure at Patna's All India Institute of Medical Sciences. He had tested positive for coronavirus, Bihar Health Secretary Sanjay Kumar said. This is the first case of highly contagious COVID-19 reported from the state. He is probably the youngest person in the country to die after contracting the infection. In Maharashtra, the state that has reported maximum coronavirus cases across India (74), a 63-year-old man admitted to a private hospital in Mumbai died this morning. "The patient had a chronic history of diabetes, high blood pressure and ischemic heart disease," Mumbai's civic body, the Brihamumbai Municipal Corporation, said in a statement. He developed acute respiratory distress syndrome leading to his death. This is the second death in Mumbai linked to coronavirus, which originated in China and has spread to over 140 countries. Three deaths have been reported from Delhi, Punjab and Karnataka this month. All of these patients were above 60.